載入中
NASDAQHealthcareBiotechnology
最新資料
US$24.4014
−US$0.3386 · -1.37%
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
一般交易時段
US$24.4014
−US$0.3386 · -1.37%
盤中時間採用ET。市場資料可能有所延遲。
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
日內區間
目前US$24.4014
52週區間
目前US$24.4014
盤中時間採用ET。市場資料可能有所延遲。
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
日內區間
目前US$24.4014
52週區間
目前US$24.4014
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.84億 USD | 3655.5萬 USD | 878萬 USD | 1240.5萬 USD | — |
| 毛利 | 1.84億 USD | 3655.5萬 USD | 878萬 USD | 1240.5萬 USD | — |
| 研究與開發 | 1.38億 USD | 8913.3萬 USD | 8223.1萬 USD | 7783.7萬 USD | 5416.8萬 USD |
| 銷售、一般及管理費用 | 6708.8萬 USD | 4879.4萬 USD | 4132.2萬 USD | 3892.4萬 USD | 3189.7萬 USD |
| 營業費用 | 2.05億 USD | 1.38億 USD | 1.24億 USD | 1.17億 USD | 8606.5萬 USD |
| 利息收入 | 1376.5萬 USD | 1263.8萬 USD | 990.8萬 USD | 312.2萬 USD | 12萬 USD |
| 利息支出 | 9000 USD | — | — | — | — |
| 折舊和攤銷 | 177萬 USD | 217.7萬 USD | 246.9萬 USD | 154.6萬 USD | 97.4萬 USD |
| 營業利益 | −2059萬 USD | −1.01億 USD | −1.15億 USD | −1.04億 USD | −8606.5萬 USD |
| 淨利 | −688.5萬 USD | −8898.1萬 USD | −1.05億 USD | −1.01億 USD | −8580.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$51.00
上漲空間 109.00%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5901.32萬0.00%2.3兆 USD0.03%US$381.51-0.11%
iShares Russell 2000 ETFIWM3559.17萬0.05%787.4億 USD0.19%US$278.14-0.29%
State Street SPDR S&P Biotech ETFXBI3194.79萬0.32%98.74億 USD0.35%US$151.33-1.59%
Vanguard Extended Market ETFVXF2029.21萬0.02%954億 USD0.05%US$233.8-0.51%
iShares Russell 2000 Growth ETFIWO1259.25萬0.09%139.17億 USD0.24%US$353.93-0.80%
iShares Biotechnology ETFIBB1027.84萬0.09%108.2億 USD0.44%US$204.18-1.12%
Vanguard Russell 2000 ETFVTWO987.82萬0.05%180億 USD0.06%US$112.36-0.27%
Dimensional - US Small Cap ETFDFAS839.74萬0.02%338.69億 USD0.31%US$78.37+0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
